Replies to post #6813 on Avid Bioservices Inc (CDMO)

[xzoneclone]

Well newyork,

Honestly, speak for yourself....

I am quite happy the way this issue has appreciated for me....

and look forward to seeing more in the future...

Honestly, there is much room on the top side and not much on the bottom the way i see it....

[jazzbeerman]

newyork,

The previous UU placement stipulated no placements below that price (roughly $1.25 "IIRC") for 90 days.


Yesterday's UU placement stipulated no placements below $2.50 for 180 days.

I am more comfortable with this placement. The financings have continued to improve over the past few years- no warrants included in the last several placements, and now- the promise of no placements for six months, or no placements under 2.50 for six months.

Again, I think this is the least of the evils. I would not want to see them give away anything too early. Would rather scrape along like this while more data comes in. They've got enough money now to fund trials til we see data from the cancer trial, HCV single-dose 6mg cohort, HCV multi-dose trial, and hopefully we'll also hear of preclinical SIV or SHIV data, and start of HIV trial, and obviously govt multi-viral data. All that- with this placement, over the next six months. - and PPHM remains sole owner of all bavi tech, for a less than 10 percent dilution.

Fine by me.

Whadya want- revenues?... :)

As for trading, good luck, sincerely.



j

[lafont]

I think we have to realize that a pharm such as PPHM is not going to walk into Goldman Sachs for their financing, and let's face it, it takes money to do what they are doing. They might have a great product, they might have a bust, but the major investment bankers are not about to bet on them at this point.

So we are faced with financing from these PIPEs for the immediate future, and it is an expensive way to finance. However, the alternatives are probably even more expensive.

If PPHM ultimately has no product, it won't matter how they financed their research, we investors are going to be big losers.

If they do have a blockbuster product, it won't matter either, as we investors are going to be big winners.

So why worry?